Biological  therapy  in  the  treatment  of  melanoma by Georgescu, Simona Roxana et al.
Journal of Mind and Medical Sciences
Volume 5 | Issue 2 Article 5
2018
Biological therapy in the treatment of melanoma
Simona Roxana Georgescu
Carol Davila University of Medicine and Pharmacy, Department of Dermatology and Venereology, Bucharest, Romania,
simonaroxanageorgescu@yahoo.com
Mihaela Roxana Ioghen
Victor Babes Hospital for Infectious and Tropical Diseases, Department of Dermatology, Bucharest, Romania,
huhu_mihaela_roxana@yahoo.ro
Maria Isabela Sarbu
Carol Davila University of Medicine and Pharmacy, Department of Dermatology and Venereology, Bucharest, Romania,
isabela_sarbu@yahoo.com
Alexandra-Florentina Ion
Victor Babes Hospital for Infectious and Tropical Diseases, Department of Dermatology, Bucharest, Romania,
florentinaalexandraion@yahoo.com
Ela Ghita
Victor Babes Hospital for Infectious and Tropical Diseases, Department of Dermatology, Bucharest, Romania,
musaela@yahoo.com
See next page for additional authors
Follow this and additional works at: https://scholar.valpo.edu/jmms
Part of the Dermatology Commons, and the Oncology Commons
This Review Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in Journal of Mind and Medical
Sciences by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at scholar@valpo.edu.
Recommended Citation
Georgescu, Simona Roxana; Ioghen, Mihaela Roxana; Sarbu, Maria Isabela; Ion, Alexandra-Florentina; Ghita, Ela; Mitran, Cristina-
Iulia; Mitran, Madalina-Irina; Benea, Vasile; and Tampa, Mircea (2018) "Biological therapy in the treatment of melanoma," Journal of
Mind and Medical Sciences: Vol. 5 : Iss. 2 , Article 5.
DOI: 10.22543/7674.52.P169175
Available at: https://scholar.valpo.edu/jmms/vol5/iss2/5
Biological therapy in the treatment of melanoma
Authors
Simona Roxana Georgescu, Mihaela Roxana Ioghen, Maria Isabela Sarbu, Alexandra-Florentina Ion, Ela
Ghita, Cristina-Iulia Mitran, Madalina-Irina Mitran, Vasile Benea, and Mircea Tampa
This review article is available in Journal of Mind and Medical Sciences: https://scholar.valpo.edu/jmms/vol5/iss2/5










Maria-Isabela Sarbu, Carol Davila University of Medicine and Pharmacy, 
Department of Dermatology and Venereology, Bucharest, Romania 
E-mail: isabela_sarbu@yahoo.com  
 
To cite this article: Georgescu SR, Ioghen MR, Sarbu MI, Ion AF, Ghita E, Mitran CI, Mitran 
MI, Benea V, Tampa M. Biological therapy in the treatment of melanoma. J Mind Med Sci. 
2018; 5(2): 169-175. DOI: 10.22543/7674.52.P169175 
 
















Biological therapy in the treatment of 
melanoma 
 Simona-Roxana Georgescu1,2, Mihaela-Roxana Ioghen2, Maria-Isabela Sarbu1,2*, 
Alexandra-Florentina Ion2, Ela Ghita2, Cristina-Iulia Mitran2, Madalina-Irina Mitran2, 
Vasile Benea2, Mircea Tampa1,2 
 
1Carol Davila University of Medicine and Pharmacy, Department of Dermatology, Bucharest, Romania 
2Victor Babes Hospital for Infectious and Tropical Diseases, Department of Dermatology, Bucharest,  
   Romania 
  
Abstract Melanoma is one of the most aggressive tumors and its incidence is on the rise. The 
low rates of survival in metastatic melanoma has led to the development of new drugs 
for this type of patient, such as biological therapy which has shown remarkable results. 
This therapy is based on stimulation of the immune system to fight tumoral cells through: 
injection of cytokines with immunomodulatory properties (interleukin-2, alpha-
interferon), vaccination with tumor antigens or immune cells that process tumor 
antigens, adoptive immunotherapy, inhibition of immune checkpoints (PD-1, CTLA-4), 
inhibition or stimulation of immune modulator molecules (OX-40, LAG-3), inhibition 
of signaling pathways involved in cell proliferation (Raf/MAPK/ERK signaling 
pathway), or administration of oncolytic viruses. Biological therapy in melanoma has 
shown promise in laboratory and clinical studies, with more therapeutic targets to be 
revealed as new molecular and cellular mechanisms of the disease are discovered.   
  












Highlights ✓ Biological therapeutic options for melanoma have considerably increased life expectancy 
of the patients. 
✓ Current therapeutic approaches are related to the tumors associated immunosuppression, 
as well as messengers related to cell growth. 
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Introduction 
Melanoma is one of the most aggressive malignant 
tumors. The incidence is on the rise - from 2005 to 2014, 
the rate increased by 3% per year among men and 
women older than 50, but remained stable among those 
younger than age 50. At the same time, given early 
diagnosis and therapeutic progress, the 5-year relative 
survival rates have also increased from 80% for the 
period 1975-1977 to 92% nowadays. Nevertheless, 5-
year relative survival rate in locally invasive or 
metastatic melanoma is 20%, which has led to the 
development of therapies which target this last group of 
patients (1). The introduction of biological therapy, also 
called immunotherapy, in the treatment of melanoma 
has shown remarkable results. This outcome is not 
surprising since melanoma is considered one of the most 
immunogenic tumors. Exposure to ultraviolet 
wavelengths promote mutagenesis and formation of 
neoantigens which then are recognized as "non-self" by 
the host's immune system (2).  
 Biological therapy can trigger or help the immune 
system fight tumoral cells in different ways: (I) 
stimulation of non-specific antitumoral response via 
cytokines, (II) vaccination, (III) and adoptive 
immunotherapy (2, 3).  
Discussions 
I Cytokines 
 a) IL-2 
 IL-2 is a cytokine secreted mainly by antigen-
stimulated CD4+ T helper cells, but it can also be 
secreted by CD8+ T cells, natural killer (NK) cells, NKT 
cells, activated dendritic cells (DC), and mast cells. IL-
2 has pleiotropic effects on the immune system: it is a 
trophic factor for lymphocytes, enhances the 
proliferation, activation, and differentiation of T 
lymphocytes and NK cells, and plays a key role in 
immune regulation via its effects on regulatory T cells 
(Treg). IL-2 was first termed "T-cell growth factor" 
upon its discovery and it revolutionized immunology 
research as it was one of the first cytokines tested in 
patients and approved to treat cancer. IL-2 was FDA 
approved in 1998 for the treatment of metastatic 
melanoma (3–6). In a study using high dose (HD) bolus 
IL-2 to treat melanoma patients, complete regression of 
the tumor was observed in 6.6% of the patients and this 
condition was maintained from 12 to more than 148 
months. Partial regression was obtained in 15% of the 
patients and was maintained from 2 to 35 months (7). 
IL-2 therapy is recommended by guidelines as a second-
line systemic treatment in metastatic or unresectable 
melanoma or as local therapy, injection in the tumor 
after surgical treatment in stage III melanoma with in-
transit metastasis or satellites without metastatic nodes 
(8).   
 There are several limitations to the use of IL-2 as 
immunotherapy. It acts on both effector T cells (Teff) 
and on Treg cells, thus having the ability to modulate the 
Teff/Treg ratio resulting in either stimulation or 
diminution of the immune response. It was 
demonstrated that low doses of IL-2 dampen the auto-
immune responses by supporting the maintenance of 
Treg cells while high doses boost the anti-tumoral 
immune responses by stimulating effector T cells. The 
amount of cytokine needed for a certain type of immune 
response is dictated by the fact that different immune 
cells express different types of IL-2 receptors. 
Nevertheless, the in vitro effect is hard to translate in 
vivo, on laboratory animals and especially on patients. 
This may be one reason why IL-2 works only on a 
fraction of patients (4, 6). One of the disadvantages is 
the toxicity of high-dose therapy. IL-2 stimulates the 
production of other cytokines which leads to lymphoid 
infiltration and results in a capillary leak syndrome. The 
immediate effect is hypovolemia and accumulation of 
fluid in the extravascular space. Thus, systemic IL-2 use 
is limited to patients with good performance status and 
is administered under strict observation (9, 10).  
 b) IFN-α 
 Interferons (IFNs) are cytokines with 
immunomodulatory properties. IFNs were first 
described for their antiviral effect but recently, it was 
discovered that they also play a role in immune 
responses to cancer by their effect on dendritic cells. 
Dendritic cells are sentinel antigen-presenting cells. 
Encountering of DC with tumor antigens leads to their 
activation, migration into the lymph nodes, cooperation 
with other immune cells, and initiation of the 
antitumoral immune response. Type I IFNs (alpha and 
beta) promote the activation, migration, and antigen-
presentation of DC. Moreover, type I IFNs have direct 
effects on tumor cells inducing their death through a 
series of intracellular signals and indirect effects on 
tumor cells through its anti-angiogenetic function 
(11,12). IFN-alpha is recommended by guidelines in (a) 
stage IIB and stage IIC melanoma with negative sentinel 
lymph node as adjuvant therapy after wide excision of 
the tumor, (b) clinical stage III as adjuvant therapy after 
wide excision and complete therapeutic lymph node 
dissection, and (c) stage III clinical satellite or in-transit 
as primary local therapy if the tumor cannot be 
surgically removed (8).  
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II Vaccination 
 Melanoma vaccines are vaccines containing 
tumoral antigens. Despite the significant success of 
microbial vaccines, cancer vaccines have demonstrated 
relatively little clinical benefit. Amongst the reasons for 
this are the difficulty of finding a target antigen and the 
capacity of the tumor cells to escape immune 
surveillance. Tested vaccines have focused on several 
kinds of antigens: (a) tumor lysate, (b) non-mutated self 
antigens - shared by tumoral cells, early embryogenetic 
cells and healthy cells in low amounts, and (c) 
neoantigens - mutated „non-self” antigens expressed 
only by tumor cells which can be shared by more 
patients or personalized for each patient. Vaccines exist 
in 2 main forms: (a) vaccines that comprise the antigen 
peptides in their composition, thus initiating the immune 
response upon immune cells’ encounter with the antigen 
or (b) vaccines can be administered in the form of 
dendritic cells loaded with antigen peptides. In this 
form, dendritic cells are challenged with the antigen in 
vitro, they process the antigen and then are administered 
to the patient (13). Murine models, as well as clinical 
trials, have demonstrated that vaccines alone are not 
sufficient but they can increase the efficiency of other 
therapies. For example, gp100 vaccines increase the 
efficacy of IL-2 therapy (14).   
 A recent study used vaccines targeting up to 20 
personalized neoantigens per patient following curative 
surgical removal in patients with untreated high-risk 
melanoma (stage IIIB/C and IVM 1a/b).  Four of the six 
vaccinated patients had no recurrence at 25 months post-
vaccination. Two had progressive disease and were 
treated with anti-PD-1 therapy (pembrolizumab) which 
led to complete tumor regression (15).  
III Adoptive immunotherapy 
 Adoptive immunotherapy is a technique by which 
T-cells are harvested from the patient and reinfused into 
the patient after expansion in cultures. Cells can be 
harvested either (a) in the form of tumor infiltrating 
lymphocytes, which are considered antigen-specific or 
(b) in the form of peripheral blood mononuclear cells 
which are then engineered to become tumor antigen-
specific. The technique is based on the fact that T-cell 
responses are specific, robust, and have memory, 
suggesting that this type of immune response can target 
tumor antigens from throughout the body (including 
metastasis), promising a therapeutic effect that may last 
several years (16).   
 Adoptive cell therapy trials using T-cells from 
tumor-infiltrating lymphocytes show 40-50% response 
rates of adoptive T-cell therapy following IL-2 treatment 
with a significant proportion of patients alive and free of 
disease 3-5 years after the treatment (17).  
 Considering that T-cells recognize antigens through 
interaction between their TCR receptor and the epitope 
presented on MHC molecules of the antigen-presenting 
cell, several techniques have been developed in order to 
genetically engineer TCR to become antigen-specific. 
One of the most promising techniques is the 
construction of chimeric antigen receptors for T cells 
(CAR-T). CAR-T therapy with CD19 as target antigen 
used in B-cell malignancies resulted in complete 
remission in 50-90% of the patients.  Nevertheless, 
clinical trials using CAR-T with GD2 as target antigen 
on solid tumors, including melanoma, have not  
been very promising, being limited by the 
immunosuppressive microenvironment of solid tumors. 
Moreover, scarcity of tumor-specific antigens in solid 
tumors highlights the need to identify new tumor-
specific target antigens in melanoma (18, 19).  
IV Immune Checkpoint inhibitors and immune 
modulator molecules  
 a) PD-1 and CTLA-4 
 T cell activation after encountering a tumor antigen 
is a two-step process.  Antigen-presenting cells present 
the antigen epitope to T-cells on the MHC molecules. 
This is the first step towards activation of T cells. 
Completion of the activation is done through co-
stimulation, a process that requires interaction between 
B7 molecules on the APC and CD28 molecules on the T 
cell. Conversely, co-inhibitory signaling occurs between 
PD1/PD2 ligand (on APC) and PD-1 receptor (on T 
cells) or CTLA4 which competes for B7 binding (20). 
Inhibitory molecules are physiologically upregulated 
during high antigenic loads in order to limit 
immunopathology when the immune system faces 
persistent infection. This phenomenon is called immune 
exhaustion.  
A side effect of this particular physiological 
phenomenon is that tumors are also situations with high 
loads of antigen which leads to immune exhaustion and 
loss of the anti-tumoral effect of T-cells (21). Therefore, 
anti-CTLA-4 and anti- PD-1 antibodies block the 
inhibition of T-cell activation, restoring the function of 
T-cells (20).   
 A Phase III clinical trial on stage III/IV melanoma 
patients comparing nivolumab (anti-PD-1 antibody) and 
ipilimumab (anti-CTLA-4 antibody) showed 44% 
response and 6.9 months progression-free survival 
among patients treated with nivolumab compared to 
19%- and 2.8-months progression-free survival among 
those treated with ipilimumab. Administration of both 
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nivolumab and ipilimumab resulted in higher response 
rates (58%) and survival (11.5 months) (22).  
Limitations of the treatment include, besides mild 
side effects, severe side effects related to immune 
stimulation such as inflammation pneumonitis, 
interstitial nephritis, colitis, and exacerbation of pre-
existing auto-immune disorders (psoriasis) or onset of 
new ones (diabetes mellitus) (20).  
 b) CD40 
 CD40 is a molecule expressed mainly on certain 
subsets of antigen presenting cells, such as monocytes, 
macrophages, and dendritic cells. CD40 ligand (CD40-
L) is expressed on a large number of cell types, 
including activated CD4 T cells, activated B cells, 
memory CD8 T cells, activated natural killer cells, 
granulocytes, endothelial cells, and macrophages. CD40 
ligation has been demonstrated to enhance the capacity 
of dendritic cells to present antigens to CD8 T cell 
antigen by increasing the expression of co-stimulatory 
molecules such as CD80 and CD86 and by increasing 
the expression of immunostimulatory cytokines. Thus, 
activating CD40 has the potential to bridge innate and 
adaptive immunity by triggering an antitumor T cell 
response (23).  
Several CD40 agonists have been developed for use 
in clinical trials for various types of cancer. CP 870,893 
monoclonal antibody is a CD40 agonist used in a phase 
1 clinical trial for recurrent and stage IV melanoma in 
combination with tremelimumab (anti CTLA-4). This 
research is still ongoing and results have not yet been 
published (23, 24). CP 870, 893 has also been used in 
combination with polyIC: LC TLR-3 ligand, an 
immunostimulant and vaccine peptides in a phase 1 
clinical study on stage III and Iv melanoma also with 
unpublished results (25).  
 c) LAG-3 (Lymphocyte Activation Gene 3) 
 LAG-3 is an immune checkpoint molecule. It has a 
role in antigen processing and presentation via MHC 
class II protein binding, negative regulation of T cell 
activation and IL-2 biosynthesis, and positive regulation 
of cytotoxicity through NK cells (26).  
 In a clinical trial that combined therapy with 
nivolumab and anti-LAG antibody in patients refractory 
to previous immunotherapies, the overall response rate 
was 13 %. The results were preliminary, as the clinical 
trial is still ongoing (27).   
 d) Oncolytic viruses 
 Oncolytic viruses have 2 mechanisms of action: (a) 
infection of the tumor cells which results in the direct 
killing of tumor cells, and (b) the fact that tumor cells 
are also infected cells will additionally trigger the innate 
and adaptive immune response. Oncolytic viruses are 
genetically engineered in order to decrease their 
pathogenicity and increase their immunogenicity (28–
30). 
 Talimogene laherparepvec (T-VEC) 
 T-VEC is the first used oncolytic virus. It is a 
genetically manipulated Herpes Simplex Virus – 1. Due 
to genetic engineering, the virus is unable to replicate in 
normal cells, has completely lost the tropism for 
neurons, and replicates preferentially in tumor cells. 
Further changes in its genome have made it possible to 
prevent the rapid clearance of the virus, resulting in 
more profound oncolytic effects and making the virus 
lose the capacity to avoid the immune response, 
resulting in a stronger immune response against infected 
tumor cells. Moreover, T-VEC has inserted in its 
genome copies of the human Granulocyte Macrophage-
Colony Stimulation Factor gene. Thus, inside a tumor 
cell, the virus replicates and secretes GM-CSF leading 
to the lysis of the tumor cell which is followed by the 
release of tumor antigens, GM-CSF and viruses. GM-
CSF release leads to tumor site infiltration with dendritic 
cells and generation of T cell immune response against 
infected tumor cells (28–30). 
 A phase III clinical trial on patients with unresected 
stage IIIB to stage IV melanoma has shown an overall 
response rate of 26.4% and a median survival rate of 
23.3 months (29). The encouraging results and the fact 
that T-VEC was well tolerated has led to T-VEC being 
the first oncolytic virus approved for melanoma therapy 
(28).   
 e) OX40 
 OX40 (CD134) is a co-stimulatory molecule on the 
antigen presenting cells and its ligand, OX40L (CD252), 
is expressed on a variety of cells, mostly activated CD4 
and CD8 T cells. It increases clonal expansion of 
effector T-cells and generation of memory T-cells 
specific for a certain antigen. It also diminishes the 
immunosuppressive effect of T regulatory cells, which 
leads to amplification of the immune response (31–33). 
 Currently, five molecules are being used for 
targeting of OX40. A phase I clinical trial on patients 
with metastatic cancers (melanoma, renal cancer, 
prostate cancer, ureteral cancer and cholangio-
carcinoma) showed regression of at least one metastasis 
in 30% of the patients (33).  
V Therapy based on Raf/MAPK/ERK signaling 
pathway inhibition 
 Raf/MAP-kinase/ERK signaling pathway is a 
membrane-to-nucleus group of proteins that 
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communicates a signal from a receptor on the surface of 
the cell to the nucleus; it is involved in a wide variety of 
cellular functions, such as cell proliferation, cell-cycle 
arrest, and apoptosis (34). BRAF gene is a proto-
oncogene that encodes for a protein (B-raf) involved in 
cell proliferation, differentiation, and survival by 
regulating the Raf/MAP-kinase/ERK signalling 
pathway. BRAF mutations were discovered in various 
types of cancers, including 40-60% of melanomas. The 
mutation results in the substitution of valine with 
glutamic acid at codon 600 (V600E). Vemurafenib and 
dabrafenib are BRAF V600E inhibitors approved by 
Food and Drug Administration (FDA) (35).  A clinical 
study on vemurafenib in patients with BRAF V600E 
mutation–with unresectable or metastatic melanoma—
included 337 patients that received vemurafenib 
treatment and 338 patients that received dacarbazine 
treatment. The overall response rate was 48.4% in the 
vemurafenib treatment group compared to 5.5% in the 
dacarbazine treatment group (36).  
Other molecules acting on Raf/MAPK/ERK 
signaling pathway are drugs that inhibit MAPK kinase 
MEK1 and/or MEK2 (MEK inhibitors). The 
combination of the two types of molecules acting on the 
same signaling pathway is useful, as resistance to 
BRAF-inhibitors can develop. A double-blind phase 3 
clinical study treated 212 patients with dabrafenib and 
trametinib (MEK inhibitor) and 213 patients with 
dabrafenib only. Overall survival was 74% at 1 year and 
51% at 2 years in the combined therapy group versus 
68% and 42%, respectively, in the dabrafenib only 
group (37). 
Conclusions 
Biological therapy for the treatment of melanoma 
has increased life expectancy in melanoma patients. 
Current options are mainly based on overcoming the 
immunosuppression that accompanies the tumor by 
enhancing the anti-tumoral immune response as well as 
regulating signal transduction related to cell growth. The 
immune system and cellular signaling cascades 
represent very complex jigsaw puzzles with some pieces 
that are still unknown and some pieces that are known 
but are not yet entirely assembled. The more pieces of 
the puzzle are discovered and assembled, the more 
biological therapeutic targets are revealed and new 
therapeutic agents are developed, thus making 
biological therapy a very promising therapeutical area 
for the treatment of metastatic melanoma. 
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